Emcure Pharmaceuticals Reports Robust Q2FY26 Performance with 13% Revenue Growth and 25% Profit After Tax Growth
Ahmedabad, November 13: Emcure Pharmaceuticals (BSE:544210, NSE: EMCURE) today announced its consolidated financial results for the quarter ended September 30th, 2025.
The quarter saw strong performance from both Domestic and International businesses.
Domestic business grew 10.6% led by strong performance across all our key therapies and aided by new initiatives. Domestic business remains a key focus and we continue to enhance our product portfolio and strengthen the team for the business. We recently announced a strategic partnership with Novo Nordisk to launch Poviztra®, biological injectable semaglutide, in India. As part of the agreement, Emcure will be the exclusive distributor responsible for the commercialization and promotion of Poviztra. Poviztra® is indicated for chronic weight management and reduction in the risk of major adverse cardiovascular events in individuals with overweight or obesity. During the quarter we also completed the acquisition of the minority stake in our Zuventus subsidiary.
International business continues to see strong performance and grew 16%. Europe saw strong growth of 23% led by new launches and aided by Manx ramp-up. Canada continues to see robust growth and grew 18%. Rest of the World business saw sustained momentum led by non-ARV business.
Revenue break-up:
| Rs Cr | 2Q26 | 2Q25 | YOY% | 1Q26 | QOQ% |
| Revenue from operations | 2,270 | 2,002 | 13.4% | 2,101 | 8.0% |
| Domestic | 1,031 | 933 | 10.6% | 995 | 3.6% |
| International | 1,238 | 1,069 | 15.8% | 1,106 | 12.0% |
| EM | 446 | 411 | 8.6% | 360 | 23.9% |
| EU | 444 | 362 | 22.7% | 403 | 10.2% |
| CA | 348 | 296 | 17.5% | 342 | 1.5% |
Contd.
Performance Summary (Consolidated)
| Rs Cr | 2Q26 | 2Q25 | YOY% | 1Q26 | QOQ% |
| Revenue from operations | 2,270 | 2,002 | 13.38% | 2,101 | 8.06% |
| Material Cost | 889 | 789 | 12.79% | 802 | 10.91% |
| Gross Profit | 1,381 | 1,213 | 13.76% | 1,299 | 6.30% |
| Gross Profit Margins | 60.82% | 60.61% | 61.82% | ||
| Employee Costs | 385 | 356 | 8.16% | 393 | -2.25% |
| Other expenses | 557 | 477 | 16.71% | 501 | 11.05% |
| EBITDA | 439 | 381 | 15.24% | 404 | 8.67% |
| EBITDA Margins | 19.34% | 19.02% | 19.23% | ||
| Other Income | 3 | 36 | 4 | ||
| Depreciation and Amortisation | 105 | 97 | 99 | ||
| Finance Costs inc. Forex | -4 | 46 | 27 | ||
| Exceptional Items | 0 | 0 | 4 | ||
| Profit Before Tax (PBT) | 341 | 273 | 24.87% | 291 | 17.42% |
| Tax | 90 | 72 | 76 | ||
| Profit After Tax (PAT) | 251 | 202 | 24.72% | 215 | 17.03% |
| PAT Margins | 11.07% | 10.07% | 10.23% |
(Disclaimer: The information provided here is investment advice only. Investing in the markets is subject to risks and please consult your advisor before investing.)
(સ્પષ્ટતા: અત્રેથી આપવામાં આવતી તમામ પ્રકારની માહિતી કોઇપણ પ્રકારે રોકાણ/ ટ્રેડીંગ માટેની સલાહ નથી. બજારોમાં રોકાણ જોખમોને આધીન છે અને રોકાણ કરતા પહેલા કૃપા કરીને તમારા સલાહકારની સલાહ લો.)
